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ABSTRACT 
Background and Objectives：Time-phasic development of nitrate tolerance in cardiovascular diseases is very important because it 
can contribute to the advent of blunted vasodilation or rebound ischemia even during continuous NTG treatment. In such a condition, 
we should change the therapeutic regimen of nitrate treatment to prevent the worsening of symptoms. Materials and Methods：We 
created a nitrate-tolerant rat model using an osmotic minipump, and we examined the hemodynamic response to bolus NTG infusion 
in vivo. We checked the phosphodiesterase (PDE)1A1 mRNA and protein level by relative quantitative RT-PCR and western blot 
analysis. We used 8-cpt-cGMP for investigating the development of a time-phasic nitrate tolerance mechanism after nitrate infusion. 
Results：NTG-treated rats revealed a significant decrease in NTG-induced MAP drop (nitrate tolerance) from 1-day and this continued 
to the third day. The mRNA and protein levels of PDE1A1 similarly increased during these periods. Conclusion：This study revealed 
the development of time-phasic nitrate tolerance from the the aspects of in vivo hemodynamic responses and PDE 1A1 gene expression, 
and our work supports the need for further investigation to come up with a different therapeutic strategy and new drugs. (Korean 
Circulation J 2005;35:94-99) 
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Introduction 
 
Organic nitrates have been used for rapid relief of angina 
pectoris for over 100 years. The major action of organic ni-
trates is to decrease the VSMC tone that leads to dilation of 
the peripheral and coronary arteries, as well as dilation of the 
peripheral veins.1) Within the VSMCs, it is recognized that 
organic nitrates (RONO2) are converted to short-lived S-ni-
trosothiols (RSNO), and they then activate guanylate cyclase 
for stimulating cGMP formation.2)3) cGMP leads to vasodila-
tion by decreasing intracellular Ca2+ via the reuptake of Ca2+ 
by the sarcoplasmic reticulum, and also by reducing the cell 
permeability to extracellular Ca2+.4) The endogenous vaso-
dilator released from the vascular endothelium, endothelium-
derived relaxing factor (EDRF or NO), also activates 
guanylate cyclase. The fact that nitrates may have a role as a 
physiological substitute for EDRF has led to a revival of 
interest in organic nitrates for the treatment of angina. Howe-
ver, the long-term therapeutic effect of nitrates is limited by 
nitrate tolerance. The sustained administration of organic 
nitrates has long been recognized to result in the rapid deve-
lopment of tolerance to their anti-anginal and hemodynamic 
effects in both human and experimental animals (nitrate 
tolerance).5-7) The basis for this nitrate tolerance is still not 
completely understood, but various mechanisms have been 
proposed to explain this phenomenon. These mechanisms are 
1) impaired nitrate biotransformation,8) 2) intracellular sulfhy-
dryl group depletion,9) 3) neurohumoral counter-regulation,10) 
4) overproduction of ROS,11) and 5) alteration in the activities 
of such key enzymes as guanylate cyclase (GC) and cyclic 
nucleotide phosphodiesterase (PDE), which regulate cGMP 
levels.12)13) It is probable that clinical nitrate tolerance is 
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caused by several of these mechanisms. Among these mecha-
nisms, the role of PDE to hydrolyze cGMP in nitrate tolerance 
has recently been investigated.14)15) 
Five different families of PDEs have been identified in 
VSMCs from humans and animals, including Ca2+/CaM-sti-
mulated PDE (PDE1) preferentially hydrolyzing cGMP, 
cGMP-stimulated PDE (PDE2) hydrolyzing both cGMP and 
cAMP, cGMP-inhibited PDE (PDE3) preferentially hydroly-
zing cAMP, cAMP-specific PDE (PDE4) hydrolyzing cAMP, 
and cGMP-specific PDE (PDE5) hydrolyzing cGMP.16) Each 
different PDE plays a distinct role in controlling the vascular 
tone. The presence of more than one PDE (PDE1 and PDE5) 
that are capable of hydrolyzing cGMP in VSMCs suggests a 
complex interplay between the enzymes. One concept is that 
PDE1 plays a dominant role when smooth muscle is exposed 
to stimuli that increase intracellular Ca2+. Thus, PDE1 is the 
major enzyme for the hydrolysis of cGMP in rabbit aorta 
stimulated with norepinephrine (NE) or KCl, which increa-
ses the intracellular calcium concentration.17) In addition, we 
have already demonstrated that nitrate tolerance is associated 
with the upregulation of Ca2+/CaM-stimulated PDE (PDE-
1A1).13) 
As a clinical concern, the time point in the development of 
nitrate tolerance for angina pectoris patients is very important 
because it can contribute to the development of blunted vaso-
dilation or rebound ischemia even during continuous NTG 
administration,18) and in such a condition the physician should 
change the therapeutic regimen of nitrate to prevent rebound 
angina. The present study investigated the time phasic deve-
lopment of nitrate tolerance in relation to the in vivo hemo-
dynamic responses and PDE 1A1 gene expression. 
 
Materials and Methods 
 
Development of nitrate tolerance in vivo 
Male Sprague-Dawley rats (Charles River Labs, 250 g to 
300 g each) were anesthetized with ketamine 40 mg/kg, xy-
lazine 0.5 mg/kg and acepromazine 5 mg/kg i.p. plus 1/3 the 
loading dose as needed. An osmotic minipump (model 2ML1: 
Alza Corp) filled with either NTG (Zeneca Inc., Wilmington, 
DE, n=16) or vehicle (propylene glycol, n=6) was subcu-
taneously implanted at the dorsum of the neck. NTG was then 
infused at an average rate of 10 μg/kg/min for 1, 2 and 3 days. 
At the end of each infusion period, the animals were sacrificed 
and dissected, and their thoracic aortas were taken and snap-
frozen in liquid nitrogen after removal of the adventitia, and 
the aortas were then stored at -80℃ until use. 
 
Hemodynamic responses to subsequent nitroglycerin bolus 
infusion 
To assess for nitrate tolerance, the hypotensive effect of 
NTG was examined. The rats’ mean arterial pressure (MAP) 
was continuously monitored by means of a catheter in the 
right common carotid artery and using a polygraph recorder 
(Grass Instruments). Bolus doses of nitroglycerin of 1, 10,100 
and 300 μg/kg i.v. were administered in a volume of 0.5 mL 
saline through the right jugular vein. Evaluating nitrate tole-
rance with multiple doses of nitroglycerin took less than 20 
minutes, and the maximum decrease in MAP was recorded 
for each dose. Hydralazine hydrochloride was then infused 
into both groups of rats as a NO-independent hypotensive 
agent (1 mg/kg, i.v.) (Fig. 1). 
 
Quantitative reverse transcription-polymerase chain reaction 
(RT-PCR) 
Tissue RNA was extracted from the aortas using a Total 
RNA Isolation Kit (Ambion) based on manufactured protocol. 
First strand cDNA was synthesized from 5 μg of total RNA 
by using random primers with the SuperScript Preamplifica-
tion System (GIBCO BRL) according to manufacture’s pro-
tocol. Quantitative RT-PCR was performed with 18s rRNA 
as an internal control using Ambion’s competimer technology. 
PDE1A1 specific primers (sense 5’-AAGATGACTGGAG-
GGATCTTCG-3’, antisense 5’-GAAAATGGAAGCCCTA-
ATTCAGC-3’) was used to generate a 281-bp PCR product 
for PDE1A1. The PCR products were then run on a 2% 
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Fig. 1. Hypotensive effect of bolus i.v. doses of nitroglycerin in ve-
hicle and nitroglycerin-pretreated rats for 1, 2 and 3 days. Values
are expressed as the % change from the baseline. *: p<.05 vs
baseline within each group. MAP: mean arterial pressure. 
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agarose gel, stained with ethidium bromide and quantified 
using image analysis software (NIH Image 1.60) (Fig. 2). 
 
Western blot analysis  
PDE1A1 protein levels were determined by Western blot 
analysis. Tissue extracts were prepared as above. The tissue 
extract was centrifuged at 1000 g for 10 min at 4℃ to remove 
the cell debris. The supernatant was boiled in 1X sample buf-
fer for 5 minutes, then loaded onto a SDS-polyacrylamide 
gel and electrophoresed. The separated proteins were trans-
ferred onto nitrocellulose membranes and next immunostained 
with PDE1-specific antibody (donated by University of Wa-
shington, Seattle, US). The immunoreactivity was detected 
by enhanced chemiluminescence using HRP-conjugated goat 
anti-rabbit IgG and a HRP-luminescent substrate mixture. 
 
VSMC culture 
Rat aortic VSMCs were isolated from 200-250 g male 
Harlan Sprague-Dawley rats and they were maintained in 10% 
bovine calf serum (BCS) with Dulbecco’s modified Eagle’s 
medium as described previously 21. The rat aortic VSMCs 
(passages 7 to 12) at 70% confluence in 100 mm dishes were 
growth-arrested by incubation in 0.1% BCS DMEM for 48 
hours prior to the indicated drug treatment. 
 
The effects of cGMP on PDE1A1 gene expression in rat aortic 
VSMCs 
We measured the PDE1A1 mRNA levels in rat aortas trea-
ted with cGMP analogue (8-chrolophenylthio(cpt)-cGMP) 
at the the indicated time. Rat aortic VSMCs were cultured and 
exposed to 8-cpt-cGMP (25 uM) for 0, 24, 48 and 72 hours. 
The total RNA was extracted and the PDE1A1 mRNA levels 
were assayed by quantitative RT-PCR as described above.  
 
Statistical analysis 
One-way or 2-way ANOVA was used to compare differen-
ces between the treatment means, and the differences were 
expressed as means±SD. After ANOVA, comparison of 2 
populations was made by Students unpaired t-test. p<0.05 
were considered as statistically significant. 
 
Results 
 
Induction of in vivo tolerance 
There was no significant difference of the baseline MAP 
between the control group and the NTG-pretreated group 
(104.3±3.9 vs. 100.8±4.1 mmHg, respectively) (Table 1). 
For the control rats, acute NTG challenges caused dose-de-
pendent decreases in the MAP ranging from 15.7±2.3% to 
37.6±1.8% (Fig. 1). The NTG-treatment group revealed sig-
Table 1. Hemodynamic responses to subsequent i.v. bolus infusion of NTG 
 Control (n=6) 1d-NTG (n=5) 2d-NTG (n=5) 3d-NTG (n=6) 
Baseline MAP (mmHg) -104.3±3.9 -100.5±8.0* -103.3±3.1* -100.8±4.1* 
Max% Δ MAP 0-37.6±1.8 0-26.8±5.1* 0-27.2±0.3* 0-17.5±1.4* 
Max% Δ MAP (HDZ) 0-28.7±2.0 0-27.5±1.0* 0-31.5±0.7* 0-28.9±1.7* 
Max% Δ MAP: maximum % decrease in MAP after i.v. bolus NTG (1, 10, 100 and 300 ug/kg), MAP: mean arterial pressure, HDZ: hydrala-
zine, NTG: nitroglycerin. *: p<0.01, compared to control group 
 
Fig. 2. Determination of linear range of PCR cycles (A) and optimal 18S rRNA ratio (B) (primer: competimer) for optimization of quantita-
tive RT-PCR. 18S rRNA: 18S ribosomal RNA, RT-PCR: reverse transcription polymerase chain reaction, PDE: phosphodiesterase. 
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nificant decreases in NTG-induced MAP drop compared to 
control values, from 3.4±2.0% to 26.8±5.1% (the 1 day-
NTG group), from 3.9±0.1% to 27.2±0.3% (the 2 day-
NTG group), from 3.9±0.7% to 17.5±1.4% (the 3 day-
NTG group) along with the NTG dose increment; this indi-
cated that changes in MAP were significantly blunted in the 
NTG-pretreated groups from the first day after NTG treatment 
and the changes in MAP were remarkably blunted on day 3. 
The hydralazine induced decrease in MAP (1 mg/kg, bolus) 
was not different for both groups (Table 1), indicating that 
the NO-independent vasodilation was similar in both groups. 
 
The mRNA & protein level of PDE1A1 Is increased in nitrate-
tolerant rats aorta 
To determine the mRNA levels of PDE1A1 for each of the 
treatment periods, quantitative RT-PCR using PDE1A1 spe-
cific primers was performed (Fig. 2). PDE1A1 mRNA levels 
in rat aorta of NTG-treated group according to the time pe-
riods were increased by 1.9±0.2, 2.0±0.3 and 2.4±0.2 fold, 
respectively, compared to the values of the control group 
(Fig. 3A). The PDE1A1 protein level was also increased 
about 2-2.3 fold in the tolerant vessels at the similar periods 
(Fig. 3B). 
 
8-cpt-cGMP upregulates PDE1A1 mRNA gene expression 
The cGMP analogue (8-cpt-cGMP, 25 uM) increased 
PDE1A1 mRNA by 2.0-2.1 fold, suggesting that the chronic 
cGMP increase stimulated by NTG treatment induced the 
PDE1A1 gene expression, and this protein subsequently hy-
drolyzes the cGMP. These findings suggest that the upregu-
lation of PDE1A1 (and the decreased cGMP) is an important 
mechanism for the development of nitrate tolerance (Fig. 4). 
 
Discussion 
 
Organic nitrates have been safely used as vasodilators for 
more than 100 years for the treatment of hypertension, ische-
mic heart disease and heart failure. Unfortunately, the thera-
peutic effect of nitrates is limited by the rapid development 
of tolerance (nitrate tolerance). Nitrate tolerance has been 
documented as the significant blunting of the hypotensive, 
vasodilatory capacity and also the supersensitivity to vaso-
constrictors, which leads to vasoconstriction.  
The present study supports the results of a previous study 
that in vivo NTG treatment of rats induces nitrate tolerance 
and this is caused by the increase of PDE1A1 gene expres-
sion.13) The upregulation of PDE1A1 provided a new mecha-
nism to explain, in part, the decreased sensitivity of the 
vasculature to NTG and the enhanced vasoconstriction obser-
ved in response to chronic NTG treatment; in addition, it 
Fig. 3. PDE1A1 gene expression using PDE1A1 specific primers (A) & PDE1A1 protein expression using PDE1A1 specific antibody (B) in
control and nitroglycerin-pretreated rat aorta for 1, 2 and 3 days. PDE: phosphodiesterase. 
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Fig. 4. Effect of in vitro 8-cpt-cGMP on PDE1A1 mRNA Expression
in VSMC 5 ug of total RNA was amplified by RT-PCR for 27 cycles
using18s rRNA as an internal control run on a 2% agarose EtBr
gel (n=7). EtBr: ethidium bromide, 8-cpt-cGMP: 8-chrolophenyl-
thio-cyclicGMP, PDE: phosphodiesterase, mRNA: messanger RNA,
VSMC: vascular smooth muscle cell. 
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explains the rebound phenomenon observed in response to 
the acute interruption of chronic NTG therapy.13)20) 
 
Mechanisms underlying nitrate tolerance 
Contraction studies with isolated aorta rings pretreated with 
NTG for several days have also shown the decreased sensiti-
vity to NTG in the absence of the neurohormonal environment, 
and this suggests the intrinsic abnormalities of the tolerant 
vasculature itself (called true vascular tolerance). Another 
phenomenon that is frequently encountered during chronic 
NTG treatment is enhanced sensitivity of the vasculature to 
several vasoconstrictors. In these studies, it was demonstrated 
that the sensitivity of the tolerant vasculature to vasocons-
trictors such as NE, Ang II, ET-1, and serotonin21)22) is greatly 
enhanced in response to NTG treatment; this is a phenomenon 
that’s been linked to a protein kinase C-mediated mecha-
nism.23)  
Our previous study13) suggested a new mechanism, that the 
induction of PDE1A1 activity would lead to an increased 
sensitivity of vasoconstrictors via the attenuation of cGMP 
accumulation in the nitrate tolerant vessels. 
  
Time-phasic development of nitrate tolerance 
Stewart et al24) first described nitrate tolerance to the anti-
hypertensive effect of NTG despite a 160-fold dose increase. 
Many studies have revealed that nitrate tolerance effect on 
heart rate and blood pressure occurred within several hours 
to several days.10)25-33) These wide time variations of tolerance 
development did not depend on the methods of administration. 
Many reports have shown the development of tolerance within 
24 to 48 hrs of the initiation of therapy in approximately half 
of patients with CHF who received an infusion of IV NTG.  
Our study has also shown similar results for the attenuation 
of MAP drop and the upregulation of PDE1A1 gene expres-
sion associated with nitrate tolerance. Significant attenuation 
of the MAP drop and the upregulation of PDE1A1 gene 
expression developed within 24 hours of chronic infusion and 
these effects were slightly increased till 72 hours. We already 
knew that nitrate tolerance develops after continuous 3 days 
NTG treatment.13) Our current study showed the much earlier 
development of nitrate tolerance for the hemodynamic res-
ponses and PDE1A1 gene expression. 
Many strategies have been suggested to prevent the pheno-
menon of nitrate tolerance such as the administration of 
sulfhydryl donors (N-acetylcysteine, methionine and sulfhy-
dryl containg ACE inhibitors), but the only clinical approach 
that has gained acceptance is a nitrate free interval. However, 
by using intermittent therapy, the increased frequency of 
anginal attacks (termed rebound angina) has been observed.34) 
In some cases, the rebound phenomenon can be a serious 
problem and may even result in sudden cardiac death.35) This 
rebound effect is believed to be associated with the increased 
sensitivity to vasoconstrictors in the nitrate-treated vessels.36) 
From the results of our study we should consider using other 
therapeutic strategies to prevent or modify nitrate tolerance 
such as intermittent dosing, and we should also further inves-
tigate possible new drugs such as PDE1A1-specific inhibitors. 
 
Study limitations 
This in vivo study was not performed for earlier time peri-
ods, like for 6 to 12 hours of NTG treatment, and it was also 
not performed for longer periods of more than 3 days. 
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